Skip to main content
SpringerLink
Log in

Substance use disorders and schizophrenia: A question of shared glutamatergic mechanisms

  • Published:
Neurotoxicity Research Aims and scope Submit manuscript

Abstract

Schizophrenia is noted for the remarkably high prevalence of substance use disorders (SUDs) including nicotine (>85%), alcohol and stimulants. Mounting evidence supports the hypothesis that the endophenotype of schizophrenia involves hypofunction of a subpopulation of cortico-limbic NMDA receptors. Low doses of NMDA receptor antagonists such as ketamine replicate in normal volunteers positive, negative and cognitive symptoms of schizophrenia as well as associated physiologic abnormalities such as eye tracking and abnormal event related potentials. Genetic studies have identified putative risk genes that directly or indirectly affect NMDA receptors including D-amino acid oxidase, its modulator G72, proline oxidase, mGIuR3 and neuregulin. Clinical trials have shown that agents that directly or indirectly enhance the function of the NMDA receptor at its glycine modulatory site (GMS) reduce negative symptoms and in the case of D-serine and sarcosine improve cognition and reduce positive symptoms in schizophrenic subjects receiving concurrent anti-psychotic medications. Notably, the GMS partial agonist D-cydoserine exacerbates negative symptoms in clozapine responders whereas full agonists, glycine and D-serine have no effects, suggesting clozapine may act indirectly as a full agonist at the GMS of the NMDA receptor. Clozapine treatment is uniquely associated with decreased substance use in patients with schizophrenia, even without psychologic intervention. Given the role of NMDA receptors in the reward circuitry and in substance dependence, it is reasonable to speculate that NMDA receptor dysfunction is a shared pathologic process in schizophrenia and co-morbid SUDs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Abbott LF (1994) Decoding neuronal firing and modelling neural networks.Q. Rev. Biophys. 27, 291–331.

    PubMed  CAS  Google Scholar 

  • Abbott LF and KI Blum (1996) Functional significance of long-term, potentiation for sequence learning and prediction.Cereb. Cortex 6, 406–416.

    Article  PubMed  CAS  Google Scholar 

  • Addington AM, M Gornick, AL Sporn, N Gogtay, D Greenstein, M Lenane, P Gochman, N Baker, R Balkissoon, RK Vakkalanka, DR Weinberger, RE Straub and JL Rapoport(2004) Polymorphisms in the 13q33.2 gene G72/G30 are associated with childhood-onset schizophrenia and psychosis not otherwise specified.Biol. Psychiatry 55, 976–980.

    Article  PubMed  CAS  Google Scholar 

  • Adler CM, AK Malhotra, I Elman, T Goldberg, M Egan, D Pickar and A Breier (1999) Comparison of ketamine-induced thought disorder in healthy volunteers an thought disorder in schizophrenia.Am. J. Psychiatry 156, 1646–1649.

    PubMed  CAS  Google Scholar 

  • Auer DP, M Wilke, A Grabner, JO Heidenreich, T Bronisch and TC Wetter (2001) Reduced NAA in the thalamus and altered membrane and glial metabolism in schizophrenic patients detected by1H-MRS and tissue segmentation.Schizophr. Res. 52, 87–99.

    Article  PubMed  CAS  Google Scholar 

  • Benes FM and S Berretta (2001) GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder.Neuropsychopharmacology 25, 1–27.

    Article  PubMed  CAS  Google Scholar 

  • Benes FM, SL Vincent, A Marie and Y Khan (1996) Upregulation of GABAA receptor binding on neurons of the prefrontal cortex in schizophrenic subjects.Neuroscience. 75, 1021–1031.

    Article  PubMed  CAS  Google Scholar 

  • Bergeron R, JT Coyle, G Tsai and RW Greene (2005) NAAG reduces NMD A receptor current in CA1 hippocampal pyramidal neurons of acute slices and dissociated neurons.Neuropsychopharmacology 30, 7–16.

    Article  PubMed  CAS  Google Scholar 

  • Bienkowski P, P Krzascik, E Koros, W Kostowski, A Scinska and W Danysz (2001) Effects of a novel uncompetitive NMD A receptor antagonist, MRZ 2/579 on ethanol self-administration and ethanol withdrawal seizures in the rat.Eur. J. Pharmacol. 413, 81–89.

    Article  PubMed  CAS  Google Scholar 

  • Bisaga A, SD Comer, AS Ward, P Popik HD Leber and MW Fichman (2001) The NMD A antagonist memantine attenuates the expression of opioid physical dependence in humans.Psychopharmacology (Bed.) 157, 1–10.

    Article  CAS  Google Scholar 

  • Blasi G, VS Mattay, A Bertolino, B Elvevag, JH Callicott, S Das, BS Kolachana, MF Egan, TE Goldberg and DR Weinberger (2005) Effect of catechol-O-methyltransferase vall 58met genotype on attentional control.J. Neurosci. 25, 5038–5045.

    Article  PubMed  CAS  Google Scholar 

  • Braff DL, MA Geyer and NR Swerdlow (2001) Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies.Psychopharmacology (Berl.) 156, 234–258.

    Article  CAS  Google Scholar 

  • Bressan RA, K Erlandsson, JM Stone, RS Mulligan, JH Krystal, PJ Ell and LS Pilowsky (2005) Impact of schizophrenia and chronic antipsychotic treatment on [123I]CNS-1261 binding to N-methyl-D-aspartate receptorsin vivo.Biol Psychiatry 58, 41–46.

    Article  PubMed  CAS  Google Scholar 

  • Butler PD, V Zemon, I Schechter, AM Saperstein, MJ Hoptman, KO Lim, N Revheim, G Silipo and DC Javitt (2005) Early-stage visual processing and cortical amplification deficits in schizophrenia.Arch. Gen. Psychiatry 62, 495–504.

    Article  PubMed  Google Scholar 

  • Cano-Cebrian MJ, T Zornoza-Sabina, C Guerri, A Polache and L Granero (2003) Local acamprosate modulates dopamine release in the rat nucleus accumbens through NMDA receptors: anin vivo microdialysis study.Naunyn Schmiedebergs Arch. Pharmacol. 367, 119–125.

    Article  PubMed  CAS  Google Scholar 

  • Cantor-Graae E, LG Nordstrom and TF McNeil (2001) Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden.Schizophr. Res. 48, 69–82.

    Article  PubMed  CAS  Google Scholar 

  • Chen YS, N Akula, SD Detera-Wadleigh, TG Schulze, J Thomas, JB Potashet al (2004) Findings in an independent sample support an association between bipolar affective disorder and the G72/G30 locus on chromosome 13q33.Mol. Psychiatry 9, 87–92.

    Article  PubMed  CAS  Google Scholar 

  • Chumakov I, M Blumenfeld, O Guerassimenko, L Cavarec, M Palicio, H Abderrahimet al (2002) Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia.Proc. Natl Acad. Sci. USA 99, 13675–13680.

    Article  PubMed  CAS  Google Scholar 

  • Coyle JT and G Tsai (2004) The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia.Psychopharmacology (Berl.) 174, 32–38.

    Article  CAS  Google Scholar 

  • Coyle JT, G Tsai and DC Goff (2002) Ionotropic glutamate receptors as therapeutic targets in schizophrenia.Curr. Drug Targets CNS Neurol Disord 1, 183–189.

    Article  PubMed  CAS  Google Scholar 

  • Davis JM, N Chen and ID Glick (2003) A meta-analysis of the efficacy of second-generation antipsychotics.Arch. Gen. Psychiatry 60, 553–564.

    Article  PubMed  CAS  Google Scholar 

  • Deicken RF, M Pegues and D Amend (1999) Reduced hippocampal N-acetylaspartate without volume loss in schizophrenia.Schizophr. Res. 37, 217–223.

    Article  PubMed  CAS  Google Scholar 

  • DeLisi LE, M Sakuma, AM Maurizio, M Relja and AL Hoff(2004) Cerebral ventricular change over the first 10 years after the onset of schizophrenia.Psychiatry Res. 130, 57–70.

    Article  PubMed  Google Scholar 

  • Drake RE, H Xie, GJ McHugo and AI Green (2000) The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia.Schizophr. Bull. 26, 441–449.

    PubMed  CAS  Google Scholar 

  • Duncan EJ, S Szilagyi, MP Schwartz, D Bugarski-Kirola, A Kunzova, S Negi, M Stephanides, TR Efferen, B Angrist, E Peselow, J Corwin, S Gonzenbach and JP Rotrosen (2004) Effects of D-cycloserine on negative symptoms in schizophrenia.Schizophr. Res. 71, 239–248.

    Article  PubMed  Google Scholar 

  • Erhardt S, K Blennow, C Nordin, E Skogh, LH Lindstrom and G Engberg (2001) Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia.Neurosci. Lett. 313, 96–98.

    Article  PubMed  CAS  Google Scholar 

  • Erhardt S, L Schwieler, C Emanuelsson and M Geyer (2004) Endogenous kynurenic acid disrupts prepulse inhibition.Biol. Psychiatry 56, 255–60.

    Article  PubMed  CAS  Google Scholar 

  • Evins AE, SM Fitzgerald L Wine, R Rosselli and DC Goff(2000) Placebo-controlled trial of glycine added to clozapine in schizophrenia.Am. J. Psychiatry 157, 826–828.

    Article  PubMed  CAS  Google Scholar 

  • Falls DL (2003) Neuregulins: functions, forms, and signaling strategies.Exp. Cell Res. 284, 14–30.

    Article  PubMed  CAS  Google Scholar 

  • Farren CK, FA Hameedi, MA Rosen, S Woods, P Jatlow and TR Kosten (2000) Significant interaction between clozapine and cocaine in cocaine addicts.Drug Alcohol Depend. 59, 153–163.

    Article  PubMed  CAS  Google Scholar 

  • Goff DC, G Tsai, DS Manoach and JT Coyle (1995) Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia.Am. J. Psychiatry 152, 1213–1215.

    PubMed  CAS  Google Scholar 

  • Goff DC, G Tsai, DS Manoach, J Flood, DG Darby and JT Coyle (1996) D-cycloserine added to clozapine for patients with schizophrenia.Am. J. Psychiatry 153, 1628–1630.

    PubMed  CAS  Google Scholar 

  • Goff DC, G Tsai, J Levitt, E Amico, D Manoach, DA Schoenfeldet al. (1999) A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia.Arch. Gen. Psychiatry 56, 21–27.

    Article  PubMed  CAS  Google Scholar 

  • Goff DC, L Herz, T Posever, V Shih, G Tsai, DC Henderson, O Freudenreich, AE Evins, I Yovel, H Zhang and D Schoenfeld (2005) A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients.Psychopharmacology (Bed.) 179, 144–150.

    Article  CAS  Google Scholar 

  • Gogtay N, A Sporn, LS Clasen, TF Nugent 3rd, D Greenstein, R Nicolsonet al. (2004) Comparison of progressive cortical gray matter loss in childhood-onset schizophrenia with that in childhood-onset atypical psychoses.Arch. Gen. Psychiatry 61, 17–22.

    Article  PubMed  Google Scholar 

  • Green AI, ES Burgess, R Dawson, SV Zimmet and RD Strous (2003) Alcohol and cannibis use in schizophrenia: effects of clozapine vs. risperidone.Schizophr. Res. 60, 81–85.

    Article  PubMed  Google Scholar 

  • Green AI, DT Chau, WM Keung, R Dawson, RI Mesholam and JJ Schidkraut (2004) Clozapine reduces alcohol drinking in Syrian golden hamsters.Psychiatry Res. 128, 9–20.

    Article  PubMed  CAS  Google Scholar 

  • Grunze HC, DG Rainnie, ME Hasselmo, E Barkai, EF Hearn, RW McCarleyet al. (1996) NMDA-dependent modulation of CA1 local circuit inhibition.J. Neurosci. 16, 2034–2043.

    PubMed  CAS  Google Scholar 

  • Gu Z, Q Jiang, AK Fu, NY Ip and Z Yan (2005) Regulation of NMDA receptors by neuregulin signaling in prefrontal cortex.J. Neurosci. 25, 4974–4984.

    Article  PubMed  CAS  Google Scholar 

  • Hakak Y, JR Walker, C Li, WH Wong, KL Davis, JD Buxbaumet al (2001) Genome-wide expression analysis reveals dys-regulation of myelination-related genes in chronic schizophrenia.Proc. Natl. Acad. Sci. USA 98, 4746–4751.

    Article  PubMed  CAS  Google Scholar 

  • Kanada S, T Mita, N Nishino and C Tanaka (1987) [3H]muscimol binding sites increased in autopsied brains of chronic schizophrenics.Life Sci. 40, 259–266.

    Article  Google Scholar 

  • Harrison PJ and MJ Owen (2003) Genes for schizophrenia? Recent findings and their pathophysiological implications.Lancet 361 (9355), 417–419.

    Article  PubMed  CAS  Google Scholar 

  • Harrison PJ and DR Weinberger (2005) Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence.Mol Psychiatry 10, 40–68.

    Article  PubMed  CAS  Google Scholar 

  • Hashimoto A and S Chiba (2004) Effect of systemic administration of D-serine on the levels of D- and L-serine in several brain areas and periphery of rat.Eur. J. Pharmacol. 495, 153–158.

    Article  PubMed  CAS  Google Scholar 

  • Hashimoto K, T Fukushima, E Shimizu, N Komatsu, H Watanabe, N Shinodaet al (2003) Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia.Arch. Gen. Psychiatry 60, 572–576.

    Article  PubMed  CAS  Google Scholar 

  • Hashimoto K, G Engberg, E Shimizu, C Nordin, LH Lindstrom and M lyo (2005) Reduced D-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients.Prog. Neuropsychopharmacol Biol Psychiatry 29, 767–769.

    Article  PubMed  CAS  Google Scholar 

  • Hattori E, C Liu, JA Badner, TI Bonner, SL Christian, M Maheshwariet al. (2003) Polymorphisms at the G72/G30 gene locus, on 13q33, are associated with bipolar disorder in two independent pedigree series.Am. J. Hum. Genet. 72, 1131–1140.

    Article  PubMed  CAS  Google Scholar 

  • Heckers S (2001) Neuroimaging studies of the hippocampus in schizophrenia.Hippocampus 11, 520–528.

    Article  PubMed  CAS  Google Scholar 

  • Heresco-Levy U, DC Javitt, M Ermilov, C Mordel, G Silipo and M Lichtenstein (1999) Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.Arch. Gen. Psychiatry 56, 29–36.

    Article  PubMed  CAS  Google Scholar 

  • Heresco-Levy U, M Ermilov, J Shimoni, B Shapira, G Silipo and DC Javitt (2002) Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia.Am. J. Psychiatry 159, 480–482.

    Article  PubMed  Google Scholar 

  • Heresco-Levy U, DC Javitt, R Ebstein, A Vass, P Lichtenberg, G Bar, S Catinari and M Ermilov (2005) D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia.Biol. Psychiatry 57, 577–585.

    Article  PubMed  CAS  Google Scholar 

  • Hoffman PL (2003) NMDA receptors in alcoholism.Int. Rev. Neurobiol 56, 35–82.

    Article  PubMed  CAS  Google Scholar 

  • Holzman PS, E Kringlen, S Matthysse, SD Flanagan, RB Lipton, G Cramer, S Levin, K Lange and DL Levy (1988) A single dominant gene can account for eye tracking dysfunctions and schizophrenia in offspring of discordant twins.Arch. Gen. Psychiatry 45, 641–647.

    PubMed  CAS  Google Scholar 

  • Huffacker SJ, M Ryan, P Sudhakaran, M Webster, TM Groeder and S Bahn (2003) Large scale gene chip analysis of postmortem brains from schizophrenia and bipolar affect in disorder patients. Society for Neuroscience Abstracts Program. No. 312.16.

  • Impagnatiello F, AR Guidotti, C Pesold, Y Dwivedi, H Camncho, MG Pisu, DP Uzunov, NR Smalheiser, JM Davis, GN Pandey, GD Pappas, P Tueting, RP Sharma and E Costa (1998) A decrease of reelin expression as a putative vulnerability factor in schizophrenia.Proc. Natl. Acad. Sci. USA 95, 15718–15723.

    Article  PubMed  CAS  Google Scholar 

  • Itil T, A Keskiner, N Kiremitci and JM Holden (1967) Effect of phencyclidine in chronic schizophrenics.Can. Psychiatr. Assoc. J. 12, 209–212.

    PubMed  CAS  Google Scholar 

  • Javitt DC and SR Zukin (1991) Recent advances in the phencyclidine model of schizophrenia.Am. J. Psychiatry 148, 1301–308.

    PubMed  CAS  Google Scholar 

  • Javitt DC, A Balla, H Sershen and A Lajtha (1999) Reversal of the behavioral and neurochemical effects of phencylidine by glycine and glycine transport inhibitors.Biol. Psychiatry 45, 668–679.

    Article  PubMed  CAS  Google Scholar 

  • Javitt DC, G Silipo, A Cienfuegos, AM Shelley, N Bark, M Parket al. (2001) Adjunctive high-dose glycine in the treatment of schizophrenia.Int. J. Neuropsychopharmacol. 4, 385–391.

    Article  PubMed  CAS  Google Scholar 

  • Javitt DC, L Duncan, A Balla and H Sershen (2005) Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action.Mol. Psychiatry 10, 275–287.

    Article  PubMed  CAS  Google Scholar 

  • Kavanagh DJ, J McGrath, JB Saunders, G Dore and D Clark (2002) Substance misuse in patients with schizophrenia: epidemiology and management.Drugs 62, 743–755.

    Article  Google Scholar 

  • Kegeles LS, A Abi-Dargham, Y Zea-Ponce, J Rodenhiser-Hill, JJ Mann, RL Van Heertum, TB Cooper, A Carlsson and M Lamelle (2000) Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia.Biol. Psychiatry 48, 627–640.

    Article  PubMed  CAS  Google Scholar 

  • Kirov G, MC O’Donovan and MJ Owen (2005) Finding schizophrenia genes.J. Clin. Invest. 115, 1440–1448.

    Article  PubMed  CAS  Google Scholar 

  • Korostishevsky M, M Kaganovich, A Cholostoy, M Ashkenazi, Y Ratner, D Daharyet al (2004) Is the G72/G30 locus associated with schizophrenia? single nucleotide polymorphisms, haplotypes, and gene expression analysis.Biol. Psychiatry 56, 169–176.

    Article  PubMed  CAS  Google Scholar 

  • Korostishevsky M, I Kremer, M Kaganovich, A Cholostoy, I Murad, M Muhaheed, I Bannoura, M Rietschel, M Dobrusin, U Bening-Abu-Shach, RH Belmaker, W Maier, RP Ebstein and R Navon (2005) Transmission disequilibrium and haplotype analyses of the G72/G30 locus: suggestive linkage to schizophrenia in Palestinian Arabs living in the North of Israel.Am. J. Med. Genet. B Neuropsychiatr. Genet. [Epub ahead of print].

  • Kratzer U, R Spanagel and WJ Schmidt (2003) The effect of acamprosate on the development of morphine-induced behavioral sensitization in rats.Behav. Pharmacol. 14, 351–356.

    PubMed  CAS  Google Scholar 

  • Krystal JH, LP Karper, JP Seibyl, GK Freeman, R Delaney, JD Bremneret al (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.Arch. Gen. Psychiatry 51, 199–214.

    PubMed  CAS  Google Scholar 

  • Krystal JH, IL Petrakis, G Mason, L Trevisan and DC D’Souza (2003) N-methyl-D-aspartate glutamate receptors and alcoholism: reward, dependence, treatment and vulnerability.Pharmacol Then 99, 79–94.

    Article  CAS  Google Scholar 

  • Kubicki M, R McCarley, CF Westin, HJ Park, S Maier, R Kikinis, FA Jolesz and ME Shenton (2005) A review of diffusion tensor imaging studies in schizophrenia.J. Psychiatr. Res. [Epub ahead of print].

  • Lahti AC, MA Weiler, BA Tamara Michaelidis, A Parwani and CA Tamminga (2001) Effects of ketamine in normal and schizophrenic volunteers.Neuropsychopharmacology 25, 455–467.

    Article  PubMed  CAS  Google Scholar 

  • Leiderman E, I Zylberman, SR Zukin, TB Cooper and DC Javitt (1996) Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: an open-label trial.Biol Psychiatry 39, 213–215.

    Article  PubMed  CAS  Google Scholar 

  • Lewis DA, DW Volk and T Hashimoto (2004) Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction.Psychopharmacology (Bed.) 174, 143–150.

    CAS  Google Scholar 

  • Li Q, S Clark, DV Lewis and WA Wilson (2002) NMDA receptor antagonists disinhibit rat posterior cingulate and retrosplenial cortices: a potential mechanism of neurotoxicity.J. Neurosci 22, 3070–3080.

    PubMed  CAS  Google Scholar 

  • Lieberman JA, TS Stroup, JP McEvoy, MS Swartz, RA Rosenheck, DO Perkins, RS Keefe, SM Davis, CE Davis, BD Lebowitz, J Severe and JK Hsiao (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.New Engl J. Med. 353, 1209–1223.

    Article  PubMed  CAS  Google Scholar 

  • Lipina T, V Labrie, I Weiner and J Roder (2005) Modulators of the glycine site on NMDA receptors, D-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia.Psychopharmacology (Berl) 179, 54–67.

    Article  CAS  Google Scholar 

  • Lipton SA (2005) The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low- affinity, uncompetitive antagonism.Curr. Alzheimer Res. 2, 155465.

    Article  Google Scholar 

  • Liu H, SC Heath, C Sobin, JL Roos, BL Galke, ML Blundell, M Lenane, B Robertson, EM Wijsman, JL Rapoport, JA Gogos and M Karayiorgou (2002) Genetic variation at the 22ql 1 PRODH2/ DGCR6 locus presents an unusual pattern and increases susceptibility to schizophrenia.Proc. Natl. Acad. Sci. USA 99, 3717–3722.

    Article  PubMed  CAS  Google Scholar 

  • Luby ED, BD Cohen, G Rosenbaum, JS Gottlieb and R Kelley (1959) Study of a new schizophrenomimetic drug; sernyl. AMAArch. Nenrol Psychiatry 81, 363–369.

    CAS  Google Scholar 

  • Maldonado C, O Cauli, M Rodriguez-Arias, MA Aguilar and J Minarro (2003) Memantine presents different effects from MK-801 in motivational and physical signs of morphine withdrawal.Behav. Brain Res. 144, 25–35.

    Article  PubMed  CAS  Google Scholar 

  • Matsui T, M Sekiguchi, A Hashimoto, U Tomita, T Nishikawa and K Wada (1995) Functional comparison of D-serine and glycine in rodents: the effect on cloned NMD A receptors and the extracellular concentration.J. Neurochem. 65, 454–458.

    PubMed  CAS  Google Scholar 

  • Meltzer H and S McGurk (1999) The effect of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia.Schizophr. Bull. 25, 233–255.

    PubMed  CAS  Google Scholar 

  • Meltzer HY, L Alphs, AI Green, AC Altamura, R Anand, A Bertoldiet al. (2003) Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).Arch. Gen. Psychiatry 60, 82–91.

    Article  PubMed  CAS  Google Scholar 

  • Meyer-Lindenberg A, JB Poline, PD Kohn, JL Holt, ME Egan, DR Weinberger and KF Berman (2001) Related articles, links evidence for abnormal cortical functional connectivity during working memory in schizophrenia.Am. J. Psychiatry 158, 1809–1817.

    Article  PubMed  CAS  Google Scholar 

  • Mitelman SA, L Shihabuddin, AM Brickman, EA Hazlett and MS Buchsbaum (2003) MRI assessment of gray and white matter distribution in Brodmann’s areas of the cortex in patients with schizophrenia with good and poor outcomes.Am. J. Psychiatry 160, 2154–2168.

    Article  PubMed  Google Scholar 

  • Nestler EJ (2005) Is there a common molecular pathway for addiction?Nat. Neurosci. 8, 1445–1449.

    Article  PubMed  CAS  Google Scholar 

  • Newcomer JW, NB Farber, V Jevtovic-Todorovic, G Selke, AK Melson, T Hershey, S Craft and JW Olney (1999) Ketamine- induced NMDA receptor hypofunction as a model of memory impairment and psychosis.Neuropsychopharmacology 20, 106–118.

    Article  PubMed  CAS  Google Scholar 

  • Ninan I, KE Jardemark and RY Wang (2003) Differential effects of atypical and typical antipsychotic drugs on N-methyl-D-aspartate- and electrically evoked responses in the pryramidal cells of the rat medial prefrontal cortex.Synapse 48, 66–79.

    Article  PubMed  CAS  Google Scholar 

  • Numakawa T, Y Yagasaki, T Ishimoto, T Okada, T Suzuki, N Iwata, N Ozaki, T Taguchi, M Tatsumi, K Kamijima, RE Straub, DR Weinberger, H Kunugi and R Hashimoto (2004) Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia.Hum. Mol. Genet. 13, 2699–2708.

    Article  PubMed  CAS  Google Scholar 

  • Oldendorf WH (1971) Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection.Am. J. Physiol 221, 1629–1639.

    Google Scholar 

  • Paulson L, P Martin, A Persson, CL Nilsson, E Ljung, A Westman-Brinkmalm, PS Eriksson, K Blennow and P Davidsson (2003) Comparative genome- and proteome analysis of cerebral cortex from MK-801-treated rats.J. Neurosci. Res. 71, 526–533.

    Article  PubMed  CAS  Google Scholar 

  • Petryshen TL, FA Middleton, A Kirby, KA Aldinger, S Purcell, AR Tahl, CP Morley, L McGann, KL Gentile, GN Rockwell, HM Medeiros, C Carvalho, A Macedo, A Dourado, J Valente, CP Ferreira, NJ Patterson, MH Azevedo, MJ Daly, CN Pato, MT Pato and P Sklar (2005) Support for involvement of neuregulin 1 in schizophrenia pathophysiology.Mol Psychiatry 10, 366–374.

    Article  PubMed  CAS  Google Scholar 

  • Phillips P and S Johnson (2001) How does drug and alcohol misuse develop among people with psychotic illness? A literature review.Soc. Psychiatry Psychiatr. Epidemiol. 36, 269–276.

    Article  PubMed  CAS  Google Scholar 

  • Popp RL and DM Lovinger (2000) Interaction of acamprosate with ethanol and spermine on NMDA receptors in primary cultured neurons.Eur. J. Pharmacol. 394, 221 -231.

    Article  PubMed  CAS  Google Scholar 

  • Procy shyn RM, N Ihsan and D Thompson (2001) A comparison of smoking behaviours between patients treated with clozapine and depot neuroleptics.Int. Clin. Psychopharmacol. 16, 291–294.

    Article  CAS  Google Scholar 

  • Procyshyn RM, G Tse, O Sin and S Flynn (2002) Concomitant clozapine reduces smoking in patients treated with risperidone.Eur. Neuropsychopharmacol 12, 77–80.

    Article  PubMed  CAS  Google Scholar 

  • Quarte.rm.ain D, J Mower, MF Rafferty, RL He.rt.ing and TH Lanthorn (1994) Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cyeloserine facilitates learning and retention.Eur. J. Pharmacol. 257, 7–12.

    Article  CAS  Google Scholar 

  • Radant AD, TA Bowdle, DS Cowley, ED Kharasch and PP Roy-Byrne (1998) Does ketamine-mediated N-methyl-D-aspartate receptor antagonism cause schizophrenia-like oculomotor abnormalities?Neuropsychopharmacology 19, 434–444.

    Article  PubMed  CAS  Google Scholar 

  • Rammes G, R Rupprecht, U Ferrari, W Zieglgansberger and CG Parsons (2001) The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other aminoalkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner.Neurosci. Lett. 306, 81–84.

    Article  PubMed  CAS  Google Scholar 

  • Reich DL and G Silvay (1989) Ketamine: an update on the first twenty-five years of clinical experience.Can. J. Anaesth. 36, 186–197.

    Article  PubMed  CAS  Google Scholar 

  • Ressler KJ, BO Rothbaum, L Tannenbaum, P Anderson, K Graap, E Zimand, L Hodges and M Davis (2004) Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear.Arch. Gen. Psychiatry 61, 1136–1144.

    Article  PubMed  Google Scholar 

  • Schell MJ (2004) The N-methyl D-aspartate receptor glycine site and D-serine metabolism: an evolutionary perspective.Philos. Trans. R. Soc. Lond. B. Biol. Sci. 359, 943–964.

    Article  PubMed  CAS  Google Scholar 

  • Schumacher J, RA Jamra, J Freudenberg, T Becker, S Ohlraun, AC Otteet al. (2004) Examination of G72 and D-amino-acid oxidase as genetic risk factors for schizophrenia and bipolar affective disorder.Mol Psychiatry 9, 203–207.

    Article  PubMed  CAS  Google Scholar 

  • Schwarcz R, A Rassoulpour, HQ Wu, D Medoff, CA Tamminga and RC Roberts (2001) Increased cortical kynurenate content in schizophrenia.Biol. Psychiatry 50, 521–530.

    Article  PubMed  CAS  Google Scholar 

  • Scott LJ, DP Figgitt, SJ Keam and J Waugh (2005) Acamprosate: a review of its use in the maintenance of abstinence in patients with alcohol dependence.CNS Drugs 19, 445–464.

    Article  PubMed  CAS  Google Scholar 

  • Seeman P (2002) Atypical antipsychotics: mechanism of action.Can. J. Psychiatry 47, 27–38.

    PubMed  Google Scholar 

  • Sigmundsson T, M Maier, BK Toone, SC Williams, A Simmons, K Greenwoodet al. (2003) Frontal lobe N-acetylaspartate correlates with psychopathology in schizophrenia: a proton magnetic resonance spectroscopy study.Schizophr. Res. 64, 63–71.

    Article  PubMed  Google Scholar 

  • Simmons ML, CG Frondoza and JT Coyle (1991) Immunocyto-chemical localization of N-acetyl-aspartate with monoclonal antibodies.Neuroscience 45, 37–45.

    Article  PubMed  CAS  Google Scholar 

  • Snyder SH (1981) Dopamine receptors, neuroleptics, and schizophrenia.Am. J. Psychiatry 138, 460–464.

    PubMed  CAS  Google Scholar 

  • Talbot K, WL Eidem, CL Tinsley, MA Benson, EW Thompson, RJ Smith, CG Hahn, SJ Siegel, JQ Trojanowski, RE Gur, DJ Blake and SE Arnold (2004) Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia.J. Clin. Invest. 113, 1353–1363.

    PubMed  CAS  Google Scholar 

  • Thoma RJ, FM Hanlon, SN Moses, D Ricker, M Huang, C Edgar, J Irwin, F Torres, MP Weisend, LE Adler, GA Miller and JM Canive (2005) M50 sensory gating predicts negative symptoms in schizophrenia.Schizophr. Res. 73, 311–318.

    Article  Google Scholar 

  • Trujillo KA (2002) The neurobiology of opiate tolerance, dependence and sensitization: mechanisms of NMDA receptor-dependent synaptic plasticity.Neurotoxicity Res. 4, 373–391.

    Article  CAS  Google Scholar 

  • Tsai G, LA Passani, BS Slusher, R Carter, L Baer, JE Kleinmanet al. (1995) Abnormal excitatory neurotransmitter metabolism in schizophrenic brains.Arch. Gen. Psychiatry 52, 829–836.

    PubMed  CAS  Google Scholar 

  • Tsai G, P Yang, LC Chung, N Lange and JT Coyle (1998) D-serine added to antipsychotics for the treatment of schizophrenia.Biol Psychiatry 44, 1081–1089.

    Article  PubMed  CAS  Google Scholar 

  • Tsai GE, P Yang, LC Chung, IC Tsai, CW Tsai and JT Coyle (1999) D-serine added to clozapine for the treatment of schizophrenia.Am. J. Psychiatry 156, 1822–1825.

    PubMed  CAS  Google Scholar 

  • Tsai G, HY Lane, P Yang, MY Chong and N Lange (2004) Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.Biol. Psychiatry 55, 452–456.

    Article  PubMed  CAS  Google Scholar 

  • Umbricht D, L Schmid, R Koller, FX Vollenweider, D Hell and DC Javitt (2000) Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia.Arch. Gen. Psychiatry 57, 1139–1147.

    Article  PubMed  CAS  Google Scholar 

  • van der Stelt O, J Frye, JA Lieberman and A Beiger (2004) Impaired P3 generation reflects high-level and progressive neurocognitive dysfunction in schizophrenia.Arch. Gen. Psychiatry 61, 237–248.

    Article  PubMed  Google Scholar 

  • Volk DW, JN Pierri, JM Fritschy, S Auh, AR Sampson and DA Lewis (2002) Reciprocal alterations in pre- and postsynaptic inhibitory markers at chandelier cell inputs to pyramidal neurons in schizophrenia.Cereb. Cortex 12, 1063–1070.

    Article  PubMed  Google Scholar 

  • Wang X, G He, N Gu, J Yang, J Tang, Q Chenet al. (2004) Association of G72/G30 with schizophrenia in the Chinese population.Biochem. Biophys. Res. Commun. 319, 1281–1286.

    Article  PubMed  CAS  Google Scholar 

  • Watson GB, MA Bolanowski, MP Baganoff, CL Deppeler and TH Lanthorn (1990) D-cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressedin Xenopus oocytes.Brain Res. 510, 158–160.

    Article  PubMed  CAS  Google Scholar 

  • Weickert CS, RE Straub, BW McClintock, M Matsumoto, R Hashimoto, TM Hyde, MM Herman, DR Weinberger and JE Kleinman (2004) Human dysbindin (DTNBP1) gene expression in normal brain and in schizophrenic prefrontal cortex and midbrain.Arch. Gen. Psychiatry 61, 544–555.

    Article  PubMed  CAS  Google Scholar 

  • Wolf ME (2003) LTP may trigger addiction.Mol. Interv. 3, 248–252.

    Article  PubMed  CAS  Google Scholar 

  • Woo TU, RE Whitehead, DS Melchitzky and DA Lewis (1998) A subclass of prefrontal gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia.Proc. Natl Acad. Sci. USA 95, 5341–5346.

    Article  PubMed  CAS  Google Scholar 

  • Woo TU, JP Walsh and FM Benes (2004) Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subun.it NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder.Arch. Gen. Psychiatry 61 (7), 649–657.

    Article  PubMed  CAS  Google Scholar 

  • Wroblewska B, JT Wroblewski, S Pshenichkin, A Surin, SE Sullivan and JH Neale (1997) N-acetylaspartylglutamate selectively activates mGluR3 receptors in transfected cells.J. Neurochem. 69, 174–181.

    Article  PubMed  CAS  Google Scholar 

  • Yamasue H, A Iwanami, Y Hirayasu, H Yamada, O Abe, N Kurokiet al. (2004) Localized volume reduction in prefrontal, temporolimbic, and paralimbic regions in schizophrenia: an MRI parcellation study.Psychiatry Res. 131, 195–207.

    Article  PubMed  Google Scholar 

  • Yurgelun-Todd DA, JT Coyle, SA Gruber, PF Renshaw, MM Silveri, E Amico, B Cohen and DC Goff (2005) Functional magnetic resonance imaging studies of schizophrenic patients during word production: effects of D-eyeloserine.Psychiatry Res. 138, 23–31.

    Article  PubMed  CAS  Google Scholar 

  • Zakharova E, A Malyshkin, V Kashkin, O Neznanova, I Sukhotina, W Danysz and A Bespalov (2004) The NMDA receptor channel blocker memantine and opioid receptor antagonist naltrexone inhibit the saccharin deprivation effect in rats.Behav. Pharmacol. 15, 273–278.

    Article  PubMed  CAS  Google Scholar 

  • Zimmet SV, RD Strous, ES Burgess, S Kohnstamm and AI Green (2000) Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey.J. Clin. Psychopharmacol. 20, 94–98.

    Article  PubMed  CAS  Google Scholar 

  • Zornberg GL, SL Buka and MT Tsuang (2000) Hypoxicischemia-related fetal/neonatal complications and risk of schizophrenia and other nonaffective psychoses: a 19-year longitudinal study.Am. J. Psychiatry 157, 196–202.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Harvard Medical School, Department of Psychiatry, McLean Hospital, 02478, Belmont, MA, USA

    Joseph T. Coyle

Authors
  1. Joseph T. Coyle
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joseph T. Coyle.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Coyle, J.T. Substance use disorders and schizophrenia: A question of shared glutamatergic mechanisms. neurotox res 10, 221–233 (2006). https://doi.org/10.1007/BF03033359

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03033359

Keywords

Search

Navigation